Should I buy GSK shares at £14 after the Q3 trading update?

This writer thinks GSK shares appear very cheap after the Q3 results, making him wonder if now’s the time for him to invest in some.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: GSK plc

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GSK (LSE: GSK) shares fell 3.4% to 1,401p today (30 October) after the drugmaker released a trading update covering the third quarter (Q3).

This means the FTSE 100 stock is down 16% in the past six months and 21% over five years.

Should I invest in GSK shares at £14? Or is this an investment to avoid? Let’s dig in.

Should you invest £1,000 in Franklin Templeton Icav - Franklin Ftse India Ucits Etf right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Franklin Templeton Icav - Franklin Ftse India Ucits Etf made the list?

See the 6 stocks

Created with Highcharts 11.4.3GSK PriceZoom1M3M6MYTD1Y5Y10YALL30 Oct 201930 Oct 2024Zoom ▾Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '242020202020212021202220222023202320242024www.fool.co.uk

A mixed Q3

Despite its disappointing share price performance, GSK is still the UK’s eighth-largest listed company. It has a market cap of £58bn and brought in over £30bn in revenue last year.

The company reported a mixed quarter today. Sales of £8.01bn were a little below what analysts were expecting (£8.05bn), but core earnings per share (EPS) of 49.7p grew 5% and beat the forecast EPS of 43.6p.

Specialty Medicines sales grew by 19%, driven by strong performances in oncology (+94%), HIV (+12%), and respiratory/immunology (+14%). Sales in General Medicines rose by 7%, with respiratory treatment Trelegy showing strong growth of 16%.

This year so far, GSK has reported 11 positive phase 3 trials. So the pipeline is strengthening.

Offsetting this, vaccine sales slumped 15%, with shingles jab Shingrix down 7% and Arexvy (for respiratory syncytial virus (RSV) down 72%. Management now expects 2024 vaccine sales to decline by low single-digits, revising its previous forecast of low-to-mid single-digit growth.

The Arexvy development is disappointing for GSK shareholders, as it seemed like a new high-growth market. RSV is a common winter illness and revenue from this new vaccine surpassed £1bn last year.

However, a US advisory committee revised its guidelines for RSV vaccinations earlier this year, essentially capping the market. Meanwhile, Moderna has had its own RSV vaccine approved, along with Pfizer. So there’s a fair bit of competition in that market now.

Zantac settlement

Arguably the biggest development this year is the $2.2bn settlement in the US to end most of its lawsuits in relation to Zantac, the heartburn drug that allegedly caused cancer. This issue has long been a massive black cloud hanging over the stock.

In the quarter, the company booked a £1.8bn charge for the Zantac settlement, which led to a sharp drop in total operating profit. Hence the core bit in the EPS figures.

CEO Emma Walmsley said: “[We] resolved the vast majority of Zantac litigation in the quarter, to remove uncertainty and so we can focus forward. All this means we are on track to deliver our 2024 guidance.”

2024 guidance (constant exchange rates)
Sales+7%-9%
Core operating profit+11%-13%
Core EPS +10%-12%

Would I invest?

There’s always the possibility of further litigation appearing in this industry. It’s a key risk, along with clinical trial setbacks and regulatory changes.

However, the Zantac settlement figure was well below what many first feared. For me, it removes a lot of doubt and distraction.

Despite this, the shares are still trading at a steep discount to peers. In fact, the forward price-to-earnings multiple for 2025 is just 8.4. AstraZeneca‘s is double that.

Meanwhile, GSK expects to declare a full-year dividend of 60p per share. This gives the stock a decent 4.3% dividend yield, which adds further weight to the investment case, in my opinion.

I’ve already got enough sector exposure in my portfolio through Moderna and AstraZeneca. But if I hadn’t, I’d consider buying GSK shares at £14.

Pound coins for sale — 31 pence?

This seems ridiculous, but we almost never see shares looking this cheap. Yet this Share Advisor pick has a price/book ratio of 0.31. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 31p they invest!

Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.

What’s more, it currently boasts a stellar dividend yield of around 10%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?

See the full investment case

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in AstraZeneca Plc and Moderna. The Motley Fool UK has recommended AstraZeneca Plc and GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Down 25% since January, this resilient dividend stock’s catching my eye

Maintaining the UK’s rail, water, and energy infrastructure isn’t the most exciting business. But it has made this a solid…

Read more »

Investing Articles

Prediction: Unilever to outperform the FTSE 100 over the next 12 months

The FTSE 100 has made a strong start to 2025, but Stephen Wright thinks a popular dividend stock could be…

Read more »

Investing Articles

I just bought this legendary S&P 500 tech stock for my ISA, 27% off its highs

This S&P 500 stock has tanked over the last month and Edward Sheldon has snapped it up for his portfolio…

Read more »

Young black man looking at phone while on the London Overground
Investing Articles

2 beaten-down stocks to consider for an ISA after the massive market sell-off!

The stock market has had a sudden meltdown! Yet our writer thinks these two growth stocks look attractive candidates for…

Read more »

British Pennies on a Pound Note
Investing Articles

I asked ChatGPT what the best UK penny stock was. This is what it said…

Can AI find winning penny stock investments? Zaven Boyrazian puts ChatGPT to the test and discovers a potentially interesting opportunity.

Read more »

Investing Articles

These FTSE 100 stocks could be the winners from Trump’s tariffs!

President Trump’s unpopular tariffs caused mayhem on the world’s stock markets this week. But some FTSE 100 stocks bucked this…

Read more »

Investing Articles

Are these 3 sold-off UK shares secretly screaming buys?

Despite the FTSE 100 rising, there are still plenty of struggling UK shares. But are these three sold-off stocks potential…

Read more »

Investing Articles

Is the US stock market set to crash in April?

Panic about a looming stock market crash is spreading, but what could be the tipping point? And what can investors…

Read more »